___

• ADVANCE Colloborative Group, Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Oodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D., Hamet, P., Harrap, S., Heller, S., Liu, L., Mancia, G., Mogensen, C.E., Pan, C., Poulter, N., Rodgers, A., Williams, B., Bom- point, S., De Galan, B.E., Joshi, R., Travert, F., 2008. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2572.
• American Diabetes Association, 2010. Diagnosis and classification of diabetes mellitus. Diabetes Care 33 Suppl. 1, S62-S69.
• American Diabetes Association, 2011. Standards of medical care in diabetes-2011. Diabetes Care 34 Suppl. 1, S11-S61.
• DCCT, 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group, N. Engl. J. Med. 329, 977-986.
• DCCT-EDIC, 2000. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Con- trol and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N. Engl. J. Med. 342, 381-389.
• Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P.D., Zieve, F.J., Marks, J., Davis, S.N., Hayward, R., Warren, S.R., Goldman, S., McCarren, M., Vitek, M.E., Henderson, W.G., Huang, G.D., VADT Investigators, 2009. Glucose control and vascular compli- cations in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129-139.
• Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.J. Jr, Bigger, J.T., Buse, J.B., Cushman, W.C., Genuth, S., Ismail-Beigi, F., Grimm, R.H. Jr, Probstfield, J.L., Simons-Morton, D.G., Friedewald, W.T., 2008. Action to control cardiovascular risk in diabetes. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559.
• HAPO Study Cooperative Research Group, Metzger, B.E., Lowe, L.P., Dyer, A.R., Trimble, E.R., Chaovarindr, U., Coustan, D.R., Hadden, D.R., McCance, D.R., Hod, M., McIntyre, H.D., Oats, J.J., Persson, B., Rogers, M.S., Sacks, D.A., 2008. Hyperglycemia and adverse pregnancy outcomes. N. Engl. J. Med. 358, 1991-2002.
• Holman, R.R., Paul S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 2008. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577-1589.
• International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger, B.E., Gabbe, S.G., Persson, B., Buchanan, T.A., Catalano, P.A., Damm, P., Dyer, A.R., Leiva, A., Hod, M., Kitzmiler, J.L., Lowe, L.P., McIntyre, H.D., Oats, J.J., Omori, Y., Schmidt, M.I., 2010. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglyce- mia in pregnancy. Diabetes Care 33, 676-682.
• International Expert Committee, 2009. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32, 1327-1334.
• Kitzmiller, J.L., Block, J.M., Brown, F.M., Catalano, P.M., Conway, D.L., Coustan, D.R., Gunderson, E.P., Herman, W.H., Hoffman, L.D., Inturrisi, M., Jovanovic, L.B., Kjos, S.I., Knopp, R.H., Montoro, M.N., Ogata, E.S., Paramsothy, P., Reader, D.M., Rosenn, B.M., Thomas, A.M., Kirkman, M.S., 2008. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care 31, 1060-1079.
• Martin, C.L., Albers, J., Herman, W.H., Cleary, P., Waberski, B., Greene, D.A., Stevens, M.J., Feldman, E.L., DCCT/EDIC Research Group, 2006. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 29, 340-344.
• Metzger, B.E., Buchanan, T.A., Coustan, D.R., De Leiva, A., Dunger, D.B., Hadden, D.R., Hod, M., Kitzmiller, J.L., Kjos, S.L., Oats, J.N., Pettitt, D.J., Sacks, D.A., Zoupas, C., 2007. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 30 Suppl.2, S251-S260.
• Nathan, D.M., Cleary, P.A., Backlund, J.Y., Genuth, S.M., Lachin, J.M., Orchard, T.J., Raskin, P., Zinman, B., Diabetes Control and Complica- tions Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, 2005. Intensive diabetes treat- ment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643-2653.
• Sacks, D.B., Bruns, D.E., Goldstein, D.E., Maclaren, N.K., McDonald, J.M., Parrott, M., 2002. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem. 48, 436-472.
• Selvin , E., Steffes, M.W., Zhu, H,. Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., Brancati, F.L., 2010. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N. Engl. J. Med. 362, 800-811.
• UKPDS,1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837-853.
• Zhang, X., Gregg, E.W., Williamson, D.F., Barker, L.E., Thomas, W., Bullard, K.M., Imperatore, G., Williams, D.E., Albright, A.L., 2010. A1C level and future risk of diabetes: A systematic review. Diabetes Care 33, 1665-1673.